Hepatitis B
Blood Test Could Help Predict Which Hepatitis B Patients Will Develop Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 09 June 2016 00:00
- Written by Thomas Jefferson University
A blood test that measures a set of circulating microRNAs (miRNAs) may help identify who will develop hepatitis B virus-related hepatocellular carcinoma (HCC), a type of primary liver cancer, according to research published in the May 24 online edition of OncoTarget.
EASL 2016: Hepatitis B Treatment Linked to Colorectal and Cervical Cancer
- Details
- Category: HBV Treatment
- Published on Friday, 03 June 2016 00:00
- Written by Liz Highleyman
People with hepatitis B who were treated with nucleoside/nucleotide antivirals did not have an overall higher rate of malignancies, but did show an increased incidence of colorectal and cervical cancer, underlining the need for regular screening, according to a study presented at the recent EASL International Liver Congress in Barcelona.
Hepatitis B and C Transmission Could Be Ended in the U.S., Report Says
- Details
- Category: Hepatitis B
- Published on Tuesday, 12 April 2016 00:00
- Written by National Academies of Sciences, Engineering, and Medicine
Hepatitis B and C could be eliminated as a public health threat in the U.S. by treating more people in order to end transmission and prevent progression of liver disease and death, according to a new report from the National Academies of Sciences, Engineering, and Medicine (formerly the Institute of Medicine).
EASL 2016: Antiviral Therapy Linked to Less Liver Cancer and Death in People with Mild Hepatitis B
- Details
- Category: HBV Treatment
- Published on Sunday, 08 May 2016 00:00
- Written by Liz Highleyman
Treatment with nucleoside/nucleotide antiviral therapy was associated with longer overall survival and reduced risk of developing liver cirrhosis and hepatocellular carcinoma (HCC) for hepatitis B patients with high viral load but minimal liver inflammation -- a group generally not prioritized for treatment --according to a report presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last month in Barcelona.
Cancer Is Falling Overall But Liver Cancer Is Rising, Largely Due to Hepatitis B and C
- Details
- Category: Liver Cancer/HCC
- Published on Tuesday, 15 March 2016 00:00
- Written by Liz Highleyman
Overall cancer rates have declined significantly in the U.S. over the past decade thanks to better screening and prevention, with the notable exception of liver cancer, according to a new Annual Report to the Nation on the Status of Cancer. A majority of liver cancer is caused by hepatitis B virus (HBV), which is preventable with a vaccine, or hepatitis C virus (HCV), which can now be cured in most cases.
EASL 2016: Core Inhibitor NVR 3-778 Plus Pegylated Interferon Inhibits Hepatitis B Activity
- Details
- Category: Experimental HBV Drugs
- Published on Tuesday, 26 April 2016 00:00
- Written by Liz Highleyman
NVR 3-778, an experimental drug that interferes with hepatitis B virus (HBV) capsid assembly, led to reductions in HBV DNA, HBV RNA, and hepatitis B "e" antigen (HBeAg), showing greater activity when combined with pegylated interferon, researchers reported at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) this month in Barcelona.
Survey Shows More than 800,000 in U.S. Have Hepatitis B, Half of Them Asian
- Details
- Category: HBV Epidemiology & Mortality
- Published on Thursday, 18 February 2016 00:00
- Written by Liz Highleyman
Although nearly 70 million people in the U.S. have been vaccinated against hepatitis B virus (HBV), there are still 847,000 people with evidence of infection, about 400,000 of whom are Asian, according to the latest NHANES survey results published in the February edition of Hepatology.
EASL 2016: Tenofovir Alafenamide Works Well Against Hepatitis B with Less Effect on Bones and Kidneys
- Details
- Category: Experimental HBV Drugs
- Published on Sunday, 17 April 2016 00:00
- Written by Liz Highleyman
The new tenofovir alafenamide (TAF) pro-drug is as potent against hepatitis B virus (HBV) as the current tenofovir disoproxil fumarate (TDF) formulation, but with less detrimental effects on bone and kidney biomarkers, according to a pair of studies presented at the European Association for the Study of the Liver's International Liver Congress (EASL 2016) last week in Barcelona.
Hepatitis B Vaccine, Hepatitis C Treatment Could Prevent Most Liver Cancer
- Details
- Category: Liver Cancer/HCC
- Published on Thursday, 04 February 2016 00:00
- Written by World Hepatitis Alliance
Widespread vaccination against hepatitis B virus (HBV) and prompt treatment of chronic hepatitis C virus (HCV) -- which together are the most common cause of hepatocellular carcinoma -- could prevent an estimated 80% of liver cancer deaths, according to the World Hepatitis Alliance in an announcement commemorating World Cancer Day.
More Articles...
- Latino Adults Have Hepatitis B Rates Similar to the General U.S. Population
- AASLD 2015: Hepatitis B Core Inhibitor NVR 3-778 Inhibits Viral Replication
- Chinese Herbs Taken with Lamivudine May Reduce Hepatitis B Mortality
- Tenofovir Alafenamide Is Effective Against Hepatitis B with Less Kidney and Bone Toxicity
- AASLD 2015: Coffee Linked to Reduced Liver Fibrosis in People with HBV, HCV, and NAFLD